カテゴリー： Grand View Research, 世界, 医療/バイオ

RNA治療臨床試験の世界市場2023-2030：市場規模、シェア、動向分析

◆英語タイトル：RNA Therapy Clinical Trials Market Size, Share & Trends Analysis Report By Modality, By Phase, By Therapeutic Areas (Rare Diseases, Anti-infective, Anticancer, Neurological), By Region, And Segment Forecasts, 2023 - 2030

Grand View Researchが発行した調査報告書（GRV23AUG052）◆商品コード：GRV23AUG052
◆発行会社（リサーチ会社）：Grand View Research
◆発行日：2023年7月25日
◆ページ数：150
◆レポート形式：英語 / PDF
◆納品方法：Eメール（受注後3営業日）
◆調査対象地域：グローバル
◆産業分野：医療機器
◆販売価格オプション（消費税別）
Single UserUSD5,950 ⇒換算￥904,400見積依頼/購入/質問フォーム
Multi User/Five UserUSD6,950 ⇒換算￥1,056,400見積依頼/購入/質問フォーム
Global/corporate LicenseUSD8,950 ⇒換算￥1,360,400見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いに変更可）
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。

❖ レポートの概要 ❖

RNA治療臨床試験市場の成長と動向
Grand View Research社の最新レポートによると、世界のRNA治療臨床試験市場規模は2030年までに35億米ドルに達する見込みです。2023年から2030年にかけての年平均成長率は3.84%で推移する見込みです。新興国市場の成長は、バイオテクノロジー企業や製薬企業のエスカレート、感染症や希少疾患の負担の増加、RNAベースのコビド-19ワクチンの成功率の増加、規制当局の承認、個別化医薬品の需要によるものです。

その上、RNA治療は病気の治療や予防のための有望な治療アプローチとして機能し、いくつかのRNA臨床試験の増加につながります。さらに、さまざまな種類のRNAに関する長期的な研究活動や、さまざまなヒトの病気や障害を治療するRNAの能力が、市場の強い需要につながっています。また、RNAそのものが薬物または標的として機能するRNA治療の潜在的な利点は、希少疾患や治療困難な疾患に対する新薬開発の革新的なアプローチとして機能します。

世界的に、感染症や希少疾患は依然として死因の上位を占めており、バイオテクノロジー企業や製薬企業の新薬開発への注目は高まっています。このため、RNAベースの治療法の技術革新が進み、RNA治療の臨床試験に膨大な需要が生じています。さらに、希少疾患は依然としてRNA治療が最もターゲットとする治療分野です。

さらに、米国食品医薬品局（FDA）によると、2022年12月時点で、米国では7,000を超える希少疾病が3,000万人以上の人々に影響を及ぼしているのに対し、欧州委員会によると、2023年2月時点で、欧州では最大3,600万人が希少疾病を患っています。EUには6000以上の希少疾患があります。同様に、RNAの機能と疾病予防における役割の理解が進むにつれ、様々なRNAの応用が促進されています。

COVID-19のパンデミックは、RNA治療臨床試験市場の成長に大きな影響を与えました。製薬会社やバイオテクノロジー企業がワクチン開発や研究開発活動に突然注力したため、世界中のRNA臨床試験が混乱したのは確かです。しかし、RNAベースのCOVID-19ワクチン開発に対する研究者の関心の高まりが、市場のプラス成長を支えています。さらに、他の感染症や腫瘍の適応症に対するRNAの使用にも関心が集まっています。こうした要因が市場の成長を後押ししています。

さらに、主要参入企業は、グローバルな事業展開と製品ポートフォリオの拡充を図るため、提携、契約、共同研究、上市などの戦略に取り組んでいます。例えば、2021年3月、IQVIA社は第3相COVID-19ワクチン臨床試験のためのJanssen Research & Development, LLCとの提携を発表しました。この試験では、バーチャル監視、遠隔医療技術、デジタル患者エンゲージメント戦略を組み合わせることで、遠隔試験と実地試験の両方をサポートする予定です。

RNA治療臨床試験市場レポートハイライト

- メッセンジャーRNAセグメントは、遺伝子発現に関する研究者の増加、技術の進歩がセグメント成長に寄与しているため、2022年に35.7%の最大売上シェアを獲得しました。

- フェーズIIセグメントは2022年に41.3%の収益シェアでRNA治療臨床試験市場を支配しました。RNA治療の有効性とRNA臨床試験の安全性がセグメント成長を牽引しています。

- 2022年、希少疾患分野が市場を支配し、21.8%の売上シェアを獲得しました。成長の主な要因としては、さまざまな種類の希少疾患の負担増が挙げられます。また、市場参入企業による研究開発費が市場成長の原動力となっています。

- 2022年の売上高シェアは北米が36.6%で最大です。定評のある市場プレイヤーの存在、希少疾患の負担増、RNAに関する研究活動の活発化、臨床試験の増加などが、この地域の成長を後押ししています。

- さらに、絶え間ない技術革新と臨床研究・臨床試験の増加が、この地域の市場成長を促進します。例えば、2022年12月、ModernaとMerckは、KEYTRUDA併用個別化mRNAがんワクチンであるmRNA-4157/V940の第2b相KEYNOTE-942/mRNA-4157-P201試験に言及しました。ステージIII/IVのメラノーマ患者を対象としたmRNAがんワクチンです。

- 市場を支配している主な企業は、IQVIA、Laboratory Corporation of America Holdings、ICON Plc、Charles River Laboratories International, Inc.、PPD Inc.、Syneos Health、Medpace Holdings, Inc.、Novotech、PAREXEL International Corp.、Veristat, LLCなどです。

第1章. 調査手法＆範囲
第2章. エグゼクティブサマリー
第3章. 市場変動・動向・範囲
第4章. モダリティ別分析
第5章. 臨床試験段階別分析
第6章. 治療領域別分析
第7章. 地域別分析
第8章. 競争状況

❖ レポートの目次 ❖

Table of Contents

Chapter 1. Methodology and Scope
1.1. Information Procurement
1.2. Information or Data Analysis
1.3. Market Scope & Segment Definition
1.4. Market Model
Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Market Variables, Trends, & Scope
3.1. Market Segmentation and Scope
3.2. Market Lineage Outlook
3.2.1. Parent Market Outlook
3.2.2. Related/Ancillary Market Outlook
3.3. Market Trends and Outlook
3.4. Market Dynamics
3.5. Market Driver Analysis
3.6. Market Restraint Analysis
3.7. Business Environment Analysis
3.7.1. SWOT Analysis
3.7.2. Porter’s Five Forces Analysis
3.8. COVID-19 Impact Analysis
Chapter 4. Modality Business Analysis
4.1. RNA therapy clinical trials Market: Modality Movement Analysis
4.2. RNA interference
4.2.1. RNA interference Market, 2018 – 2030 (USD Million)
4.3. Antisense therapy
4.3.1. Antisense therapy Market, 2018 – 2030 (USD Million)
4.4. Messenger RNA
4.4.1. Messenger RNA Market, 2018 – 2030 (USD Million)
4.5. Oligonucleotide, non-antisense, non-RNAi
4.5.1. Oligonucleotide, non-antisense, non-RNAi Market, 2018 – 2030 (USD Million)
Chapter 5. Clinical Trials Phase Business Analysis
5.1. RNA therapy clinical trials Market: Clinical Trials Phase Movement Analysis
5.2. Phase I
5.2.1. Phase I Market, 2018 – 2030 (USD Million)
5.3. Phase II
5.3.1. Phase II Market, 2018 – 2030 (USD Million)
5.4. Phase III
5.4.1. Phase III Market, 2018 – 2030 (USD Million)
5.5. Phase IV
5.5.1. Phase IV Market, 2018 – 2030 (USD Million)
Chapter 6. Therapeutic Areas Business Analysis
6.1. RNA therapy clinical trials Market: Therapeutic Areas Movement Analysis
6.2. Rare Diseases
6.2.1. Rare Diseases Market, 2018 – 2030 (USD Million)
6.3. Anti-infective
6.3.1. Anti-infective Market, 2018 – 2030 (USD Million)
6.4. Anticancer
6.4.1. Anticancer Market, 2018 – 2030 (USD Million)
6.5. Neurological
6.5.1. Neurological Market, 2018 – 2030 (USD Million)
6.6. Alimentary/Metabolic
6.6.1. Alimentary/Metabolic Market, 2018 – 2030 (USD Million)
6.7. Musculoskeletal
6.7.1. Musculoskeletal Market, 2018 – 2030 (USD Million)
6.8. Cardiovascular Respiratory
6.8.1. Cardiovascular Respiratory Market, 2018 – 2030 (USD Million)
6.9. Sensory
6.9.1. Sensor Market, 2018 – 2030 (USD Million)
6.10. Others
6.10.1. Others Market, 2018 – 2030 (USD Million)
Chapter 7. Regional Business Analysis
7.1. RNA therapy clinical trials Market Share By Region, 2022 & 2030
7.2. North America
7.2.1. North America RNA therapy clinical trials Market, 2018 – 2030 (USD Million)
7.2.2. U.S.
7.2.2.1. Key Country Dynamics
7.2.2.2. Regulatory Framework
7.2.2.3. Competitive Scenario
7.2.2.4. U.S. RNA therapy clinical trials Market, 2018 – 2030 (USD Million)
7.2.3. Canada
7.2.3.1. Key Country Dynamics
7.2.3.2. Regulatory Framework
7.2.3.3. Competitive Scenario
7.2.3.4. Canada RNA therapy clinical trials Market, 2018 – 2030 (USD Million)
7.3. Europe
7.3.1. Europe RNA therapy clinical trials Market, 2018 – 2030 (USD Million)
7.3.2. UK
7.3.2.1. Key Country Dynamics
7.3.2.2. Competitive Scenario
7.3.2.3. UK RNA therapy clinical trials Market, 2018 – 2030 (USD Million)
7.3.3. Germany
7.3.3.1. Key Country Dynamics
7.3.3.2. Competitive Scenario
7.3.3.3. Germany RNA therapy clinical trials Market, 2018 – 2030 (USD Million)
7.3.4. France
7.3.4.1. Key Country Dynamics
7.3.4.2. Competitive Scenario
7.3.4.3. France RNA therapy clinical trials Market, 2018 – 2030 (USD Million)
7.3.5. Italy
7.3.5.1. Key Country Dynamics
7.3.5.2. Competitive Scenario
7.3.5.3. Italy RNA therapy clinical trials Market, 2018 – 2030 (USD Million)
7.3.6. Spain
7.3.6.1. Key Country Dynamics
7.3.6.2. Competitive Scenario
7.3.6.3. Spain RNA therapy clinical trials Market, 2018 – 2030 (USD Million)
7.3.7. Sweden
7.3.7.1. Key Country Dynamics
7.3.7.2. Competitive Scenario
7.3.7.3. Sweden RNA therapy clinical trials Market, 2018 – 2030 (USD Million)
7.3.8. Norway
7.3.8.1. Key Country Dynamics
7.3.8.2. Competitive Scenario
7.3.8.3. Norway RNA therapy clinical trials Market, 2018 – 2030 (USD Million)
7.3.9. Denmark
7.3.9.1. Key Country Dynamics
7.3.9.2. Competitive Scenario
7.3.9.3. Denmark RNA therapy clinical trials Market, 2018 – 2030 (USD Million)
7.4. Asia Pacific
7.4.1. Asia Pacific RNA therapy clinical trials Market, 2018 – 2030 (USD Million)
7.4.2. Japan
7.4.2.1. Key Country Dynamics
7.4.2.2. Competitive Scenario
7.4.2.3. Japan RNA therapy clinical trials Market, 2018 – 2030 (USD Million)
7.4.3. China
7.4.3.1. Key Country Dynamics
7.4.3.2. Competitive Scenario
7.4.3.3. China RNA therapy clinical trials Market, 2018 – 2030 (USD Million)
7.4.4. India
7.4.4.1. Key Country Dynamics
7.4.4.2. Competitive Scenario
7.4.4.3. India RNA therapy clinical trials Market, 2018 – 2030 (USD Million)
7.4.5. Australia
7.4.5.1. Key Country Dynamics
7.4.5.2. Competitive Scenario
7.4.5.3. Australia RNA therapy clinical trials Market, 2018 – 2030 (USD Million)
7.4.6. South Korea
7.4.6.1. Key Country Dynamics
7.4.6.2. Competitive Scenario
7.4.6.3. South Korea RNA therapy clinical trials Market, 2018 – 2030 (USD Million)
7.4.7. Thailand
7.4.7.1. Key Country Dynamics
7.4.7.2. Competitive Scenario
7.4.7.3. Thailand RNA therapy clinical trials Market, 2018 – 2030 (USD Million)
7.5. Latin America
7.5.1. Latin America RNA therapy clinical trials Market, 2018 – 2030 (USD Million)
7.5.2. Brazil
7.5.2.1. Key Country Dynamics
7.5.2.2. Competitive Scenario
7.5.2.3. Brazil RNA therapy clinical trials Market, 2018 – 2030 (USD Million)
7.5.3. Mexico
7.5.3.1. Key Country Dynamics
7.5.3.2. Competitive Scenario
7.5.3.3. Mexico RNA therapy clinical trials Market, 2018 – 2030 (USD Million)
7.5.4. Argentina
7.5.4.1. Key Country Dynamics
7.5.4.2. Competitive Scenario
7.5.4.3. Argentina RNA therapy clinical trials Market, 2018 – 2030 (USD Million)
7.6. MEA
7.6.1. MEA RNA therapy clinical trials Market, 2018 – 2030 (USD Million)
7.6.2. South Africa
7.6.2.1. Key Country Dynamics
7.6.2.2. Competitive Scenario
7.6.2.3. South Africa RNA therapy clinical trials Market, 2018 – 2030 (USD Million)
7.6.3. Saudi Arabia
7.6.3.1. Key Country Dynamics
7.6.3.2. Competitive Scenario
7.6.3.3. Saudi Arabia RNA therapy clinical trials Market, 2018 – 2030 (USD Million)
7.6.4. UAE
7.6.4.1. Key Country Dynamics
7.6.4.2. Competitive Scenario
7.6.4.3. UAE RNA therapy clinical trials Market, 2018 – 2030 (USD Million)
7.6.5. Kuwait
7.6.5.1. Key Country Dynamics
7.6.5.2. Competitive Scenario
7.6.5.3. Kuwait RNA therapy clinical trials Market, 2018 – 2030 (USD Million)
Chapter 8. Competitive Landscape
8.1. Company Categorization
8.2. Strategy Mapping
8.2.1. Merger& Acquisition
8.2.2. Collaborations
8.2.3. New Product Launch
8.3. Participant’s overview
8.3.1. IQVIA
8.3.1.1. Overview
8.3.1.2. Financial Performance
8.3.1.3. Product Benchmarking
8.3.1.4. Strategic Initiatives
8.3.2. ICON Plc
8.3.2.1. Overview
8.3.2.2. Financial Performance
8.3.2.3. Product Benchmarking
8.3.2.4. Strategic Initiatives
8.3.3. Laboratory Corporation of America Holdings
8.3.3.1. Overview
8.3.3.2. Financial Performance
8.3.3.3. Product Benchmarking
8.3.3.4. Strategic Initiatives
8.3.4. Charles River Laboratories International, Inc.
8.3.4.1. Overview
8.3.4.2. Financial Performance
8.3.4.3. Product Benchmarking
8.3.4.4. Strategic Initiatives
8.3.5. PAREXEL International Corp.
8.3.5.1. Overview
8.3.5.2. Financial Performance
8.3.5.3. Product Benchmarking
8.3.5.4. Strategic Initiatives
8.3.6. Syneos Health
8.3.6.1. Overview
8.3.6.2. Financial Performance
8.3.6.3. Product Benchmarking
8.3.6.4. Strategic Initiatives
8.3.7. Medpace Holdings, Inc.
8.3.7.1. Overview
8.3.7.2. Financial Performance
8.3.7.3. Product Benchmarking
8.3.7.4. Strategic Initiatives
8.3.8. PPD Inc.
8.3.8.1. Overview
8.3.8.2. Financial Performance
8.3.8.3. Product Benchmarking
8.3.8.4. Strategic Initiatives
8.3.9. Novotech
8.3.9.1. Overview
8.3.9.2. Financial Performance
8.3.9.3. Product Benchmarking
8.3.9.4. Strategic Initiatives
8.3.10. Veristat, LLC.
8.3.10.1. Overview
8.3.10.2. Financial Performance
8.3.10.3. Product Benchmarking
8.3.10.4. Strategic Initiatives

List of Tables

Table 1 List of Secondary Sources
Table 2 List of Abbreviations
Table 3 Leading Market Players Anticipated to Witness Highest Growth
Table 4 Global RNA Therapy Clinical Trials Market, By Region, 2018 - 2030 (USD Million)
Table 5 Global RNA Therapy Clinical Trials Market, By Modality, 2018 - 2030 (USD Million)
Table 6 Global RNA Therapy Clinical Trials Market, By Clinical Trials Phase, 2018 - 2030 (USD Million)
Table 7 Global RNA Therapy Clinical Trials Market, By Therapeutic Areas 2018 - 2030 (USD Million)
Table 8 North America RNA Therapy Clinical Trials Market, By Country, 2018 - 2030 (USD Million)
Table 9 North America RNA Therapy Clinical Trials Market, By Modality, 2018 - 2030 (USD Million)
Table 10 North America RNA Therapy Clinical Trials Market, By Clinical Trials Phase, 2018 - 2030 (USD Million)
Table 11 North America RNA Therapy Clinical Trials Market, By Therapeutic Areas 2018 - 2030 (USD Million)
Table 12 U.S. RNA Therapy Clinical Trials Market, By Modality, 2018 - 2030 (USD Million)
Table 13 U.S. RNA Therapy Clinical Trials Market, By Clinical Trials Phase, 2018 - 2030 (USD Million)
Table 14 U.S. RNA Therapy Clinical Trials Market, By Therapeutic Areas 2018 - 2030 (USD Million)
Table 15 Canada RNA Therapy Clinical Trials Market, By Modality, 2018 - 2030 (USD Million)
Table 16 Canada RNA Therapy Clinical Trials Market, By Clinical Trials Phase, 2018 - 2030 (USD Million)
Table 17 Canada RNA Therapy Clinical Trials Market, By Therapeutic Areas 2018 - 2030 (USD Million)
Table 18 Europe RNA Therapy Clinical Trials Market, By Country, 2018 - 2030 (USD Million)
Table 19 Europe RNA Therapy Clinical Trials Market, By Modality, 2018 - 2030 (USD Million)
Table 20 Europe RNA Therapy Clinical Trials Market, By Clinical Trials Phase, 2018 - 2030 (USD Million)
Table 21 Europe RNA Therapy Clinical Trials Market, By Therapeutic Areas 2018 - 2030 (USD Million)
Table 22 UK RNA Therapy Clinical Trials Market, By Modality, 2018 - 2030 (USD Million)
Table 23 UK RNA Therapy Clinical Trials Market, By Clinical Trials Phase, 2018 - 2030 (USD Million)
Table 24 UK RNA Therapy Clinical Trials Market, By Therapeutic Areas 2018 - 2030 (USD Million)
Table 25 Germany RNA Therapy Clinical Trials Market, By Modality, 2018 - 2030 (USD Million)
Table 26 Germany RNA Therapy Clinical Trials Market, By Clinical Trials Phase, 2018 - 2030 (USD Million)
Table 27 Germany RNA Therapy Clinical Trials Market, By Therapeutic Areas 2018 - 2030 (USD Million)
Table 28 France RNA Therapy Clinical Trials Market, By Modality, 2018 - 2030 (USD Million)
Table 29 France RNA Therapy Clinical Trials Market, By Clinical Trials Phase, 2018 - 2030 (USD Million)
Table 30 France RNA Therapy Clinical Trials Market, By Therapeutic Areas 2018 - 2030 (USD Million)
Table 31 Italy RNA Therapy Clinical Trials Market, By Modality, 2018 - 2030 (USD Million)
Table 32 Italy RNA Therapy Clinical Trials Market, By Clinical Trials Phase, 2018 - 2030 (USD Million)
Table 33 Italy RNA Therapy Clinical Trials Market, By Therapeutic Areas 2018 - 2030 (USD Million)
Table 34 Spain RNA Therapy Clinical Trials Market, By Modality, 2018 - 2030 (USD Million)
Table 35 Spain RNA Therapy Clinical Trials Market, By Clinical Trials Phase, 2018 - 2030 (USD Million)
Table 36 Spain RNA Therapy Clinical Trials Market, By Therapeutic Areas 2018 - 2030 (USD Million)
Table 37 Sweden RNA Therapy Clinical Trials Market, By Modality, 2018 - 2030 (USD Million)
Table 38 Sweden RNA Therapy Clinical Trials Market, By Clinical Trials Phase, 2018 - 2030 (USD Million)
Table 39 Sweden RNA Therapy Clinical Trials Market, By Therapeutic Areas 2018 - 2030 (USD Million)
Table 40 Norway RNA Therapy Clinical Trials Market, By Modality, 2018 - 2030 (USD Million)
Table 41 Norway RNA Therapy Clinical Trials Market, By Clinical Trials Phase, 2018 - 2030 (USD Million)
Table 42 Norway RNA Therapy Clinical Trials Market, By Therapeutic Areas 2018 - 2030 (USD Million)
Table 43 Denmark RNA Therapy Clinical Trials Market, By Modality, 2018 - 2030 (USD Million)
Table 44 Denmark RNA Therapy Clinical Trials Market, By Clinical Trials Phase, 2018 - 2030 (USD Million)
Table 45 Denmark RNA Therapy Clinical Trials Market, By Therapeutic Areas 2018 - 2030 (USD Million)
Table 46 Asia Pacific RNA Therapy Clinical Trials Market, By Country, 2018 - 2030 (USD Million)
Table 47 Asia Pacific RNA Therapy Clinical Trials Market, By Modality, 2018 - 2030 (USD Million)
Table 48 Asia Pacific RNA Therapy Clinical Trials Market, By Clinical Trials Phase, 2018 - 2030 (USD Million)
Table 49 Asia Pacific RNA Therapy Clinical Trials Market, By Therapeutic Areas 2018 - 2030 (USD Million)
Table 50 Japan RNA Therapy Clinical Trials Market, By Modality, 2018 - 2030 (USD Million)
Table 51 Japan RNA Therapy Clinical Trials Market, By Clinical Trials Phase, 2018 - 2030 (USD Million)
Table 52 Japan RNA Therapy Clinical Trials Market, By Therapeutic Areas 2018 - 2030 (USD Million)
Table 53 China RNA Therapy Clinical Trials Market, By Modality, 2018 - 2030 (USD Million)
Table 54 China RNA Therapy Clinical Trials Market, By Clinical Trials Phase, 2018 - 2030 (USD Million)
Table 55 China RNA Therapy Clinical Trials Market, By Therapeutic Areas 2018 - 2030 (USD Million)
Table 56 India RNA Therapy Clinical Trials Market, By Modality, 2018 - 2030 (USD Million)
Table 57 India RNA Therapy Clinical Trials Market, By Clinical Trials Phase, 2018 - 2030 (USD Million)
Table 58 India RNA Therapy Clinical Trials Market, By Therapeutic Areas 2018 - 2030 (USD Million)
Table 59 Australia RNA Therapy Clinical Trials Market, By Modality, 2018 - 2030 (USD Million)
Table 60 Australia RNA Therapy Clinical Trials Market, By Clinical Trials Phase, 2018 - 2030 (USD Million)
Table 61 Australia RNA Therapy Clinical Trials Market, By Therapeutic Areas 2018 - 2030 (USD Million)
Table 62 South Korea RNA Therapy Clinical Trials Market, By Modality, 2018 - 2030 (USD Million)
Table 63 South Korea RNA Therapy Clinical Trials Market, By Clinical Trials Phase, 2018 - 2030 (USD Million)
Table 64 South Korea RNA Therapy Clinical Trials Market, By Therapeutic Areas 2018 - 2030 (USD Million)
Table 65 Thailand RNA Therapy Clinical Trials Market, By Modality, 2018 - 2030 (USD Million)
Table 66 Thailand RNA Therapy Clinical Trials Market, By Clinical Trials Phase, 2018 - 2030 (USD Million)
Table 67 Thailand RNA Therapy Clinical Trials Market, By Therapeutic Areas 2018 - 2030 (USD Million)
Table 68 Latin America RNA Therapy Clinical Trials Market, By Country, 2018 - 2030 (USD Million)
Table 69 Latin America RNA Therapy Clinical Trials Market, By Modality, 2018 - 2030 (USD Million)
Table 70 Latin America RNA Therapy Clinical Trials Market, By Clinical Trials Phase, 2018 - 2030 (USD Million)
Table 71 Latin America RNA Therapy Clinical Trials Market, By Therapeutic Areas 2018 - 2030 (USD Million)
Table 72 Brazil RNA Therapy Clinical Trials Market, By Modality, 2018 - 2030 (USD Million)
Table 73 Brazil RNA Therapy Clinical Trials Market, By Clinical Trials Phase, 2018 - 2030 (USD Million)
Table 74 Brazil RNA Therapy Clinical Trials Market, By Therapeutic Areas 2018 - 2030 (USD Million)
Table 75 Mexico RNA Therapy Clinical Trials Market, By Modality, 2018 - 2030 (USD Million)
Table 76 Mexico RNA Therapy Clinical Trials Market, By Clinical Trials Phase, 2018 - 2030 (USD Million)
Table 77 Mexico RNA Therapy Clinical Trials Market, By Therapeutic Areas 2018 - 2030 (USD Million)
Table 78 Argentina RNA Therapy Clinical Trials Market, By Modality, 2018 - 2030 (USD Million)
Table 79 Argentina RNA Therapy Clinical Trials Market, By Clinical Trials Phase, 2018 - 2030 (USD Million)
Table 80 Argentina RNA Therapy Clinical Trials Market, By Therapeutic Areas 2018 - 2030 (USD Million)
Table 81 Middle East and Africa RNA Therapy Clinical Trials Market, By Country, 2018 - 2030 (USD Million)
Table 82 Middle East and Africa RNA Therapy Clinical Trials Market, By Modality, 2018 - 2030 (USD Million)
Table 83 Middle East and Africa RNA Therapy Clinical Trials Market, By Clinical Trials Phase, 2018 - 2030 (USD Million)
Table 84 Middle East and Africa RNA Therapy Clinical Trials Market, By Therapeutic Areas 2018 - 2030 (USD Million)
Table 85 South Africa RNA Therapy Clinical Trials Market, By Modality, 2018 - 2030 (USD Million)
Table 86 South Africa RNA Therapy Clinical Trials Market, By Clinical Trials Phase, 2018 - 2030 (USD Million)
Table 87 South Africa RNA Therapy Clinical Trials Market, By Therapeutic Areas 2018 - 2030 (USD Million)
Table 88 Saudi Arabia RNA Therapy Clinical Trials Market, By Modality, 2018 - 2030 (USD Million)
Table 89 Saudi Arabia RNA Therapy Clinical Trials Market, By Clinical Trials Phase, 2018 - 2030 (USD Million)
Table 90 Saudi Arabia RNA Therapy Clinical Trials Market, By Therapeutic Areas 2018 - 2030 (USD Million)
Table 91 UAE RNA Therapy Clinical Trials Market, By Modality, 2018 - 2030 (USD Million)
Table 92 UAE RNA Therapy Clinical Trials Market, By Clinical Trials Phase, 2018 - 2030 (USD Million)
Table 93 UAE RNA Therapy Clinical Trials Market, By Therapeutic Areas 2018 - 2030 (USD Million)
Table 94 Kuwait RNA Therapy Clinical Trials Market, By Modality, 2018 - 2030 (USD Million)
Table 95 Kuwait RNA Therapy Clinical Trials Market, By Clinical Trials Phase, 2018 - 2030 (USD Million)
Table 96 Kuwait RNA Therapy Clinical Trials Market, By Therapeutic Areas 2018 - 2030 (USD Million)


❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer
★リサーチレポート[ RNA治療臨床試験の世界市場2023-2030：市場規模、シェア、動向分析(RNA Therapy Clinical Trials Market Size, Share & Trends Analysis Report By Modality, By Phase, By Therapeutic Areas (Rare Diseases, Anti-infective, Anticancer, Neurological), By Region, And Segment Forecasts, 2023 - 2030)]についてメールでお問い合わせはこちらでお願いします。
◆関連リサーチレポート◆
  • 浮腫臨床試験の世界市場2023-2030：市場規模、シェア、動向分析
  • 浮腫臨床試験の世界市場2023-2030：市場規模、シェア、動向分析
  • 世界の希少疾病治験市場2023-2030：市場規模、シェア、動向分析

    • ◆H&Iグローバルリサーチのお客様（例）◆